24-hydroxylase in cancer: Impact on vitamin D-based anticancer therapeutics

Journal of Steroid Biochemistry and Molecular Biology

Volumn 136, Issue 1, 2013, Pages 252-257

  Luo, Wei ^a   Hershberger, Pamela A ^a   Trump, Donald L ^a   Johnson, Candace S ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

24 hydroxylase; Anti tumor; Calcitriol; CYP24A1

Indexed keywords

1 TETRALONE DERIVATIVE; CALCITRIOL; CTA 091; GENISTEIN; KETOCONAZOLE; LIAROZOLE; MESSENGER RNA; MICRORNA 125B; OXYGENASE; RETINOID X RECEPTOR; STEROID 24 HYDROXYLASE; UNCLASSIFIED DRUG; VANILLOID RECEPTOR; VID 400; [2 (4 HYDROXYBENZYL) 6 METHOXY 3,4 DIHYDRO 2H NAPHTHALEN 1 ONE];

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; BREAST TUMOR; CANCER CELL; CANCER INCIDENCE; CANCER INHIBITION; CANCER PROGNOSIS; CELL MOTILITY; CELL PROLIFERATION; CHORIOCARCINOMA; DNA METHYLATION; DRUG BIOAVAILABILITY; DRUG HALF LIFE; EPIGENETICS; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HYDROGEN BOND; HYDROPHOBICITY; IC 50; INTRACELLULAR SIGNALING; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION INITIATION; TUMOR MICROENVIRONMENT; UPREGULATION; VITAMIN D RESPONSIVE ELEMENT;

EID: 84881165296     PISSN: 09600760     EISSN: 18791220     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2012.09.031     Document Type: Review

References (79)

1. D.D. Bikle, S. Pillai, Vitamin D, calcium, and epidermal differentiation, Endocrine Reviews 14 (1993) 3-19.
2. H.F. DeLuca, Overview of general physiologic features and functions of vitamin D, American Journal of Clinical Nutrition 80 (2004) 1689S-1696S.
3. K. Muller, K. Bendtzen, 1,25-Dihydroxyvitamin D3 as a natural regulator of human immune functions, Journal of Investigative Dermatology Symposium Proceedings 1 (1996) 68-71.
4. D.M. Peehl, R.J. Skowronski, G.K. Leung, S.T. Wong, T.A. Stamey, D. Feldman, Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells, Cancer Research 54 (1994) 805-810.
5. S. Masuda, G. Jones, Promise of vitamin D analogues in the treatment of hyperproliferative conditions, Molecular Cancer Therapeutics 5 (2006) 797-808.
6. V. Sung, D. Feldman, 1,25-Dihydroxyvitamin D3 decreases human prostate cancer cell adhesion and migration, Molecular and Cellular Endocrinology 164 (2000) 133-143.
7. H. Tanaka, E. Abe, C. Miyaura, T. Kuribayashi, K. Konno, Y. Nishii, T. Suda, 1alpha,25-Dihydroxycholecalciferol and a human myeloid leukaemia cell line (HL-60), Biochemical Journal 204 (1982) 713-719.
8. J.M. Gonzalez-Sancho, M.J. Larriba, P. Ordonez-Moran, H.G. Palmer, A. Munoz, Effects of 1alpha,25-dihydroxyvitamin D3 in human colon cancer cells, Anticancer Research 26 (2006) 2669-2681.
9. K.W. Colston, L.C. Lowe, J.L. Mansi, M.J. Campbell, Vitamin D status and breast cancer risk, Anticancer Research 26 (2006) 2573-2580.
10. X. Zhang, S.V. Nicosia, W. Bai, Vitamin D receptor is a novel drug target for ovarian cancer treatment, Current Cancer Drug Targets 6 (2006) 229-244.
11. K.C. Chiang, T.C. Chen, Vitamin D for the prevention and treatment of pancreatic cancer, World Journal of Gastroenterology 15 (2009) 3349-3354.
12. Z. Ghous, J. Akhter, M.H. Pourgholami, D.L. Morris, Inhibition of hepatocellular cancer by EB1089: in vitro and in vive study, Anticancer Research 28 (2008) 3757-3761.
13. P. White, N. Cooke, The multifunctional properties and characteristics of vitamin D-binding protein, Trends in Endocrinology & Metabolism 11 (2000) 320-327.
14. H.S. Cross, Extrarenal vitamin D hydroxylase expression and activity in normal and malignant cells: modification of expression by epigenetic mechanisms and dietary substances, Nutrition Reviews 65 (2007) S108-S112.
15. G.G. Schwartz, L.W. Whitlatch, T.C. Chen, B.L. Lokeshwar, M.F. Holick, Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3, Cancer Epidemiology, Biomarkers and Prevention 7 (1998) 391-395.
16. T.C. Chen, L. Wang, L.W. Whitlatch, J.N. Flanagan, M.F. Holick, Prostatic 25- hydroxyvitamin D-1alpha-hydroxylase and its implication in prostate cancer, Journal of Cellular Biochemistry 88 (2003) 315-322.
17. K. Townsend, K.N. Evans, M.J. Campbell, K.W. Colston, J.S. Adams, M. Hewison, Biological actions of extra-renal 25-hydroxyvitamin D-1alpha-hydroxylase and implications for chemoprevention and treatment, Journal of Steroid Biochemistry and Molecular Biology 97 (2005) 103-109.
18. D.E. Prosser, G. Jones, Enzymes involved in the activation and inactivation of vitamin D, Trends in Biochemical Sciences 29 (2004) 664-673.
19. R. St-Arnaud, CYP24A1: structure, function, and physiological role, in: D. Feldman, J.W. Pike, J.S. Adams (Eds.), Vitamin D, Elsevier, San Diego, 2011, pp. 43-56.
20. J.L. Omdahl, E.A. Bobrovnikova, S. Choe, P.P. Dwivedi, B.K. May, Overview of regulatory cytochrome P450 enzymes of the vitamin D pathway, Steroids 66 (2001) 381-389.
21. T.J. Wang, F. Zhang, J.B. Richards, B. Kestenbaum, J.B. van Meurs, D. Berry, D.P. Kiel, E.A. Streeten, C. Ohlsson, D.L. Koller, L. Peltonen, J.D. Cooper, P.F. O'Reilly, D.K. Houston, N.L. Glazer, L. Vandenput, M. Peacock, J. Shi, F. Rivadeneira, M.I. McCarthy, P. Anneli, I.H. de Boer, M. Mangino, B. Kato, D.J. Smyth, S.L. Booth, P.F. Jacques, G.L. Burke, M. Goodarzi, C.L. Cheung, M. Wolf, K. Rice, D. Goltzman, N. Hidiroglou, M. Ladouceur, N.J. Wareham, L.J. Hocking, D. Hart, N.K. Arden, C. Cooper, S. Malik, W.D. Fraser, A.L. Hartikainen, G. Zhai, H.M. Macdonald, N.G. Forouhi, R.J. Loos, D.M. Reid, A. Hakim, E. Dennison, Y. Liu, C. Power, H.E. Stevens, L. Jaana, R.S. Vasan, N. Soranzo, J. Bojunga, B.M. Psaty, M. Lorentzon, T. Foroud, T.B. Harris, A. Hofman, J.O. Jansson, J.A. Cauley, A.G. Uitterlinden, Q. Gibson, M.R. Jarvelin, D. Karasik, D.S. Siscovick, M.J. Econs, S.B. Kritchevsky, J.C. Florez, J.A. Todd, J. Dupuis, E. Hypponen, T.D. Spector, Common genetic determinants of vitamin D insufficiency: a genome-wide association study, Lancet 376 (2010) 180-188.
22. K.P. Schlingmann, M. Kaufmann, S. Weber, A. Irwin, C. Goos, U. John, J. Misselwitz, G. Klaus, E. Kuwertz-Broking, H. Fehrenbach, A.M. Wingen, T. Guran, J.G. Hoenderop, R.J. Bindels, D.E. Prosser, G. Jones, M. Konrad, Mutations in CYP24A1 and idiopathic infantile hypercalcemia, New England Journal of Medicine 365 (2011) 410-421.
23. G. Jones, D.E. Prosser, M. Kaufmann, 25-Hydroxyvitamin D-24-hydroxylase (CYP24A1): its important role in the degradation of vitamin D, Archives of Biochemistry and Biophysics 523 (2012) 9-18.
24. M.G. Anderson, M. Nakane, X. Ruan, P.E. Kroeger, J.R. Wu-Wong, Expression of VDR and CYP24A1 mRNA in human tumors, Cancer Chemotherapy and Pharmacology 57 (2006) 234-240.
25. K. Mimori, Y. Tanaka, K. Yoshinaga, T. Masuda, K. Yamashita, M. Okamoto, H. Inoue, M. Mori, Clinical significance of the overexpression of the candidate oncogene CYP24 in esophageal cancer, Annals of Oncology 15 (2004) 236-241.
26. D.R. Nelson, D.C. Zeldin, S.M. Hoffman, L.J. Maltais, H.M. Wain, D.W. Nebert, Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants, Pharmacogenetics 14 (2004) 1-18.
27. M.R. Haussler, G.K. Whitfield, C.A. Haussler, J.C. Hsieh, P.D. Thompson, S.H. Selznick, C.E. Dominguez, P.W. Jurutka, The nuclear vitamin D receptor: biological and molecular regulatory properties revealed, Journal of Bone and Mineral Research 13 (1998) 325-349.
28. B. Endres, S. Kato, H.F. DeLuca, Metabolism of 1alpha,25-dihydroxyvitamin D(3) in vitamin D receptor-ablated mice in vivo, Biochemistry 39 (2000) 2123-2129.
29. W. Zhu, P.J. Malloy, E. Delvin, G. Chabot, D. Feldman, Hereditary 1,25- dihydroxyvitamin D-resistant rickets due to an opal mutation causing premature termination of the vitamin D receptor, Journal of Bone and Mineral Research 13 (1998) 259-264.
30. J.W. Pike, M.B. Meyer, The vitamin D receptor: new paradigms for the regulation of gene expression by 1,25-dihydroxyvitamin D(3), Endocrinology and Metabolism Clinics of North America 39 (2010) 255-269, table of contents.
31. L.J. Burke, A. Baniahmad, Co-repressors 2000, FASEB Journal 14 (2000) 1876-1888.
32. C. Leo, J.D. Chen, The SRC family of nuclear receptor coactivators, Gene 245 (2000) 1-11.
33. C. Rachez, L.P. Freedman, Mechanisms of gene regulation by vitamin D(3) receptor: a network of coactivator interactions, Gene 246 (2000) 9-21.
34. C. Rachez, B.D. Lemon, Z. Suldan, V. Bromleigh, M. Gamble, A.M. Naar, H. Erdjument-Bromage, P. Tempst, L.P. Freedman, Ligand-dependent transcription activation by nuclear receptors requires the DRIP complex, Nature 398 (1999) 824-828.
35. C. Carlberg, P. Polly, Gene regulation by vitamin D3, Critical Reviews in Eukaryotic Gene Expression 8 (1998) 19-42.
36. M.B. Meyer, P.D. Goetsch, J.W. Pike, A downstream intergenic cluster of regulatory enhancers contributes to the induction of CYP24A1 expression by 1alpha,25-dihydroxyvitamin D3, Journal of Biological Chemistry 285 (2010) 15599-15610.
37. K.S. Chen, H.F. DeLuca, Cloning of the human 1alpha,25-dihydroxyvitamin D-3 24-hydroxylase gene promoter and identification of two vitamin D-responsive elements, Biochimica et Biophysica Acta 1263 (1995) 1-9.
38. C. Zierold, H.M. Darwish, H.F. DeLuca, Two vitamin D response elements function in the rat 1,25-dihydroxyvitamin D 24-hydroxylase promoter, Journal of Biological Chemistry 270 (1995) 1675-1678.
39. A. Roff, R.T. Wilson, A novel SNP in a vitamin D response element of the CYP24A1 promoter reduces protein binding, transactivation, and gene expression, Journal of Steroid Biochemistry and Molecular Biology 112 (2008) 47-54.
40. A.W. Norman, X. Song, L. Zanello, C. Bula, W.H. Okamura, Rapid and genomic biological responses are mediated by different shapes of the agonist steroid hormone, 1alpha,25(OH)2vitamin D3, Steroids 64 (1999) 120-128.
41. M. Cui, Y. Zhao, K.W. Hance, A. Shao, R.J. Wood, J.C. Fleet, Effects of MAPK signaling on 1,25-dihydroxyvitamin D-mediated CYP24 gene expression in the enterocyte-like cell line, Caco-2, Journal of Cellular Physiology 219 (2009) 132-142.
42. B.K. Nutchey, J.S. Kaplan, P.P. Dwivedi, J.L. Omdahl, A. Ferrante, B.K. May, C.S. Hii, Molecular action of 1,25-dihydroxyvitamin D3 and phorbol ester on the activation of the rat cytochrome P450C24 (CYP24) promoter: role of MAP kinase activities and identification of an important transcription factor binding site, Biochemical Journal 389 (2005) 753-762.
43. M. Cui, A. Klopot, Y. Jiang, J.C. Fleet, The effect of differentiation on 1,25 dihydroxyvitamin D-mediated gene expression in the enterocyte-like cell line, Caco-2, Journal of Cellular Physiology 218 (2009) 113-121.
44. B.S. Yang, C.A. Hauser, G. Henkel, M.S. Colman, C. Van Beveren, K.J. Stacey, D.A. Hume, R.A. Maki, M.C. Ostrowski, Ras-mediated phosphorylation of a conserved threonine residue enhances the transactivation activities of c-Ets1 and c-Ets2, Molecular and Cellular Biology 16 (1996) 538-547.
45. P.P. Dwivedi, C.S. Hii, A. Ferrante, J. Tan, C.J. Der, J.L. Omdahl, H.A. Morris, B.K. May, Role of MAP kinases in the 1,25-dihydroxyvitamin D3-induced transactivation of the rat cytochrome P450C24 (CYP24) promoter. Specific functions for ERK1/ERK2 and ERK5, Journal of Biological Chemistry 277 (2002) 29643-29653.
46. R.M. Tolon, A.I. Castillo, A.M. Jimenez-Lara, A. Aranda, Association with Ets-1 causes ligand- and AF2-independent activation of nuclear receptors, Molecular and Cellular Biology 20 (2000) 8793-8802.
47. P. Dhawan, S. Christakos, Novel regulation of 25-hydroxyvitamin D3 24- hydroxylase (24(OH)ase) transcription by glucocorticoids: cooperative effects of the glucocorticoid receptor, C/EBP beta, and the Vitamin D receptor in 24(OH)ase transcription, Journal of Cellular Biochemistry 110 (2010) 1314-1323.
48. A.A. Hidalgo, K.K. Deeb, J.W. Pike, C.S. Johnson, D.L. Trump, Dexamethasone enhances 1alpha,25-dihydroxyvitamin D3 effects by increasing vitamin D receptor transcription, Journal of Biological Chemistry 286 (2011) 36228-36237.
49. J.E. Leader, C. Wang, M. Fu, R.G. Pestell, Epigenetic regulation of nuclear steroid receptors, Biochemical Pharmacology 72 (2006) 1589-1596.
50. B. Novakovic, M. Sibson, H.K. Ng, U. Manuelpillai, V. Rakyan, T. Down, S. Beck, T. Fournier, D. Evain-Brion, E. Dimitriadis, J.M. Craig, R. Morley, R. Saffery, Placenta-specific methylation of the vitamin D 24-hydroxylase gene: implications for feedback autoregulation of active vitamin D levels at the fetomaternal interface, Journal of Biological Chemistry 284 (2009) 14838-14848.
51. M. Wjst, I. Heimbeck, D. Kutschke, K. Pukelsheim, Epigenetic regulation of vitamin D converting enzymes, Journal of Steroid Biochemistry and Molecular Biology 121 (2010) 80-83.
52. H.C. Horvath, P. Lakatos, J.P. Kosa, K. Bacsi, K. Borka, G. Bises, T. Nittke, P.A. Hershberger, G. Speer, E. Kallay, The candidate oncogene CYP24A1: A potential biomarker for colorectal tumorigenesis, Journal of Histochemistry and Cytochemistry 58 (2010) 277-285.
53. G. Chen, S.H. Kim, A.N. King, L. Zhao, R.U. Simpson, P.J. Christensen, Z. Wang, D.G. Thomas, T.J. Giordano, L. Lin, D.E. Brenner, D.G. Beer, N. Ramnath, CYP24A1 is an independent prognostic marker of survival in patients with lung adenocarcinoma, Clinical Cancer Research 17 (2011) 817-826.
54. S. Komagata, M. Nakajima, S. Takagi, T. Mohri, T. Taniya, T. Yokoi, Human CYP24 catalyzing the inactivation of calcitriol is post-transcriptionally regulated by miR-125b, Molecular Pharmacology 76 (2009) 702-709.
55. M. Khorchide, D. Lechner, H.S. Cross, Epigenetic regulation of vitamin D hydroxylase expression and activity in normal and malignant human prostate cells, Journal of Steroid Biochemistry and Molecular Biology 93 (2005) 167-172.
56. J.M. Matilainen, M. Malinen, M.M. Turunen, C. Carlberg, S. Vaisanen, The number of vitamin D receptor binding sites defines the different vitamin D responsiveness of the CYP24 gene in malignant and normal mammary cells, Journal of Biological Chemistry 285 (2010) 24174-24183.
57. D.G. Albertson, B. Ylstra, R. Segraves, C. Collins, S.H. Dairkee, D. Kowbel, W.L. Kuo, J.W. Gray, D. Pinkel, Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene, Nature Genetics 25 (2000) 144-146.
58. C. Collins, J.M. Rommens, D. Kowbel, T. Godfrey, M. Tanner, S.I. Hwang, D. Polikoff, G. Nonet, J. Cochran, K. Myambo, K.E. Jay, J. Froula, T. Cloutier, W.L. Kuo, P. Yaswen, S. Dairkee, J. Giovanola, G.B. Hutchinson, J. Isola, O.P. Kallioniemi, M. Palazzolo, C. Martin, C. Ericsson, D. Pinkel, D. Albertson, W.B. Li, J.W. Gray, Positional cloning of ZNF217 and NABC1: genes amplified at 20q13.2 and overexpressed in breast carcinoma, Proceedings of the National Academy of Sciences of the United States of America 95 (1998) 8703-8708.
59. A. Kallioniemi, O.P. Kallioniemi, J. Piper, M. Tanner, T. Stokke, L. Chen, H.S. Smith, D. Pinkel, J.W. Gray, F.M. Waldman, Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridization, Proceedings of the National Academy of Sciences of the United States of America 91 (1994) 2156-2160.
60. W. Luo, A.R. Karpf, K.K. Deeb, J.R. Muindi, C.D. Morrison, C.S. Johnson, D.L. Trump, Epigenetic regulation of vitamin D 24-hydroxylase/CYP24A1 in human prostate cancer, Cancer Research 70 (2010) 5953-5962.
61. K.K. Deeb, W. Luo, A.R. Karpf, A.R. Omilian, W. Bshara, L. Tian, M.A. Tangrea, C.D. Morrison, C.S. Johnson, D.L. Trump, Differential vitamin D 24- hydroxylase/CYP24A1 gene promoter methylation in endothelium from benign and malignant human prostate, Epigenetics 6 (2011) 994-1000.
62. G.J. Miller, G.E. Stapleton, T.E. Hedlund, K.A. Moffat, Vitamin D receptor expression, 24-hydroxylase activity, and inhibition of growth by 1alpha,25-dihydroxyvitamin D3 in seven human prostatic carcinoma cell lines, Clinical Cancer Research 1 (1995) 997-1003.
63. L.H. Ly, X.Y. Zhao, L. Holloway, D. Feldman, Liarozole acts synergistically with 1alpha,25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity, Endocrinology 140 (1999) 2071-2076.
64. R.A. Parise, M.J. Egorin, B. Kanterewicz, M. Taimi, M. Petkovich, A.M. Lew, S.S. Chuang, M. Nichols, T. El-Hefnawy, P.A. Hershberger, CYP24, the enzyme that catabolizes the antiproliferative agent vitamin D, is increased in lung cancer, International Journal of Cancer 119 (2006) 1819-1828.
65. I. Schuster, H. Egger, G. Herzig, G.S. Reddy, J.A. Schmid, M. Schussler, G. Vorisek, Selective inhibitors of vitamin D metabolism - new concepts and perspectives, Anticancer Research 26 (2006) 2653-2668.
66. T.A. Reinhardt, R.L. Horst, Ketoconazole inhibits self-induced metabolism of 1,25-dihydroxyvitamin D3 and amplifies 1,25-dihydroxyvitamin D3 receptor up-regulation in rat osteosarcoma cells, Archives of Biochemistry and Biophysics 272 (1989) 459-465.
67. D.M. Peehl, E. Seto, J.Y. Hsu, D. Feldman, Preclinical activity of ketoconazole in combination with calcitriol or the vitamin D analogue EB 1089 in prostate cancer cells, Journal of Urology 168 (2002) 1583-1588.
68. S.W. Yee, C. Simons, Synthesis and CYP24 inhibitory activity of 2-substituted- 3, 4-dihydro-2H-naphthalen-1-one (tetralone) derivatives, Bioorganic and Medicinal Chemistry Letters 14 (2004) 5651-5654.
69. S.W. Yee, M.J. Campbell, C. Simons, Inhibition of Vitamin D3 metabolism enhances VDR signalling in androgen-independent prostate cancer cells, Journal of Steroid Biochemistry and Molecular Biology 98 (2006) 228-235.
70. M.K. Shanmugam, R. Kannaiyan, G. Sethi, Targeting cell signaling and apoptotic pathways by dietary agents: role in the prevention and treatment of cancer, Nutrition and Cancer 63 (2011) 161-173.
71. H. Farhan, H.S. Cross, Transcriptional inhibition of CYP24 by genistein, Annals of the New York Academy of Sciences 973 (2002) 459-462.
72. A. Rao, A. Coan, J.E. Welsh, W.W. Barclay, C. Koumenis, S.D. Cramer, Vitamin D receptor and p21/WAF1 are targets of genistein and 1,25-dihydroxyvitamin D3 in human prostate cancer cells, Cancer Research 64 (2004) 2143-2147.
73. S. Swami, A.V. Krishnan, D.M. Peehl, D. Feldman, Genistein potentiates the growth inhibitory effects of 1,25-dihydroxyvitamin D3 in DU145 human prostate cancer cells: role of the direct inhibition of CYP24 enzyme activity, Molecular and Cellular Endocrinology 241 (2005) 49-61.
74. I. Schuster, H. Egger, P. Nussbaumer, R.T. Kroemer, Inhibitors of vitamin D hydroxylases: structure-activity relationships, Journal of Cellular Biochemistry 88 (2003) 372-380.
75. I. Schuster, H. Egger, G.S. Reddy, G. Vorisek, Combination of vitamin D metabolites with selective inhibitors of vitamin D metabolism, Recent Results in Cancer Research 164 (2003) 169-188.
76. G.H. Posner, C. Helvig, D. Cuerrier, D. Collop, A. Kharebov, K. Ryder, T. Epps, M. Petkovich, Vitamin D analogues targeting CYP24 in chronic kidney disease, Journal of Steroid Biochemistry and Molecular Biology 121 (2010) 13-19.
77. Q. Zhang, B. Kanterewicz, S. Buch, M. Petkovich, R. Parise, J. Beumer, Y. Lin, B. Diergaarde, P.A. Hershberger, CYP24 inhibition preserves 1alpha,25-dihydroxyvitamin D(3) anti-proliferative signaling in lung cancer cells, Molecular and Cellular Endocrinology 355 (2012) 153-161.
78. J.H. Beumer, R.A. Parise, B. Kanterewicz, M. Petkovich, D.Z. D'Argenio, P.A. Hershberger, A local effect of CYP24 inhibition on lung tumor xenograft exposure to 1,25-dihydroxyvitamin D(3) is revealed using a novel LC-MS/MS assay, Steroids 77 (2012) 477-483.
79. J.Y. Wang, S. Swami, A.V. Krishnan, D. Feldman, Combination of calcitriol and dietary soy exhibits enhanced anticancer activity and increased hypercalcemic toxicity in a mouse xenograft model of prostate cancer, Prostate 72 (2012) 1628-1637.